Underwriters Exercise Over-Allotment Option in Full WESTFORD, Mass., Dec. 14 /PRNewswire-FirstCall/ -- Cynosure, Inc. (NASDAQ: CYNO) today announced the completion of its initial public offering of 5,000,000 shares of its Class A common stock. Of the 5,000,000 shares sold in the offering, 4,000,000 shares were sold by Cynosure and 1,000,000 shares were sold by a wholly owned subsidiary of El.En. S.p.A., Cynosure's largest stockholder. In addition, the underwriters of Cynosure's initial public offering exercised their over-allotment option in full and purchased an additional 750,000 shares of Class A common stock from Cynosure. All of the shares were sold to the public at an initial public offering price of $15 per share. Cynosure received net proceeds from the offering, including net proceeds from the exercise of the underwriters' over-allotment option, of approximately $64.2 million after payment of underwriting discounts and commissions and estimated offering expenses. Cynosure did not receive any proceeds from the sale of the shares by the selling stockholder. The sole book-running underwriter for the offering was Citigroup Global Markets Inc. UBS Securities LLC, Jefferies & Company, Inc. and Needham & Company, LLC acted as co-managers. A copy of the final prospectus relating to this offering may be obtained by contacting Citigroup Corporate and Investment Banking, Brooklyn Army Terminal, 140 58th Street, 8th Floor, Brooklyn, NY 11220 (tel: 718-765-6732; fax: 718-765-6734). Cynosure, Inc. develops and markets aesthetic treatment systems that are used by physicians and other practitioners to perform non-invasive procedures to remove hair, treat vascular lesions, rejuvenate skin through the treatment of shallow vascular and pigmented lesions and temporarily reduce the appearance of cellulite. Cynosure's products incorporate a broad range of laser and other light-based energy sources, including Alexandrite, pulse dye, Nd:Yag and diode lasers, as well as intense pulsed light. Cynosure was founded in 1991. COMPANY CONTACT: Timothy W. Baker EVP, Chief Financial Officer (978) 256-4200 DATASOURCE: Cynosure, Inc. CONTACT: Timothy W. Baker, EVP, Chief Financial Officer of Cynosure, Inc., +1-978-256-4200

Copyright